These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9973211

  • 1. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM.
    Cancer Res; 1999 Feb 01; 59(3):633-8. PubMed ID: 9973211
    [Abstract] [Full Text] [Related]

  • 2. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM.
    Br J Cancer; 1999 May 01; 80(5-6):716-23. PubMed ID: 10360649
    [Abstract] [Full Text] [Related]

  • 3. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
    Ching LM, Goldsmith D, Joseph WR, Körner H, Sedgwick JD, Baguley BC.
    Cancer Res; 1999 Jul 15; 59(14):3304-7. PubMed ID: 10416582
    [Abstract] [Full Text] [Related]

  • 4. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z, Baguley BC, Ching LM.
    Cancer Res; 2001 Feb 15; 61(4):1517-21. PubMed ID: 11245459
    [Abstract] [Full Text] [Related]

  • 5. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
    Browne WL, Wilson WR, Baguley BC, Ching LM.
    Anticancer Res; 1998 Feb 15; 18(6A):4409-13. PubMed ID: 9891501
    [Abstract] [Full Text] [Related]

  • 6. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, Albelda SM.
    Cancer Res; 2005 Dec 15; 65(24):11752-61. PubMed ID: 16357188
    [Abstract] [Full Text] [Related]

  • 7. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA, Gollnick SO, Camacho SH, Greco WR, Cheney RT.
    Cancer Res; 2003 Nov 15; 63(22):7584-90. PubMed ID: 14633671
    [Abstract] [Full Text] [Related]

  • 8. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
    Ching LM, Joseph WR, Crosier KE, Baguley BC.
    Cancer Res; 1994 Feb 15; 54(4):870-2. PubMed ID: 8313372
    [Abstract] [Full Text] [Related]

  • 9. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F, Liu J, Ching LM, Baguley BC.
    Cancer Chemother Pharmacol; 2008 Mar 15; 61(3):497-502. PubMed ID: 17473922
    [Abstract] [Full Text] [Related]

  • 10. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
    Baguley BC, Zhuang L, Kestell P.
    Oncol Res; 1997 Mar 15; 9(2):55-60. PubMed ID: 9167186
    [Abstract] [Full Text] [Related]

  • 11. Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation.
    Perera PY, Barber SA, Ching LM, Vogel SN.
    J Immunol; 1994 Nov 15; 153(10):4684-93. PubMed ID: 7525711
    [Abstract] [Full Text] [Related]

  • 12. The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells.
    Patel S, Parkin SM, Bibby MC.
    Anticancer Res; 1997 Nov 15; 17(1A):141-50. PubMed ID: 9066644
    [Abstract] [Full Text] [Related]

  • 13. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M, Spernyak JA, Mazurchuk R, Camacho SH, Oseroff AR, Cheney RT, Bellnier DA.
    Clin Cancer Res; 2005 Jun 01; 11(11):4241-50. PubMed ID: 15930363
    [Abstract] [Full Text] [Related]

  • 14. Small-molecule cytokine inducers causing tumor necrosis.
    Baguley BC.
    Curr Opin Investig Drugs; 2001 Jul 01; 2(7):967-75. PubMed ID: 11757800
    [Abstract] [Full Text] [Related]

  • 15. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 16. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
    Philpott M, Ching LM, Baguley BC.
    Eur J Cancer; 2001 Oct 01; 37(15):1930-7. PubMed ID: 11576850
    [Abstract] [Full Text] [Related]

  • 17. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
    Chung F, Wang LC, Kestell P, Baguley BC, Ching LM.
    Cancer Chemother Pharmacol; 2004 May 01; 53(5):377-83. PubMed ID: 15060740
    [Abstract] [Full Text] [Related]

  • 18. The ability of coumarin-, flavanon- and flavonol-analogues of flavone acetic acid to stimulate human monocytes.
    Barbera M, Caputo A, Zampiron A, Gobbi S, Rampa A, Bisi A, Carrara M.
    Oncol Rep; 2008 Jan 01; 19(1):187-96. PubMed ID: 18097594
    [Abstract] [Full Text] [Related]

  • 19. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Wu Q, Quan H, Xu Y, Li Y, Hu Y, Lou L.
    J Pharmacol Exp Ther; 2012 Jun 01; 341(3):709-17. PubMed ID: 22414857
    [Abstract] [Full Text] [Related]

  • 20. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
    Philpott M, Baguley BC, Ching LM.
    Cancer Chemother Pharmacol; 1995 Jun 01; 36(2):143-8. PubMed ID: 7767951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.